PT105R

PT105R is an investigational drug developed by Peptron as a modified release formulation of a peptide-based therapy, administered in a clinical trial context to assess its safety and pharmacokinetics in healthy postmenopausal female volunteers. It is closely related to PT105, another Peptron compound, and is being evaluated in a phase 1 clinical study comparing these two compounds. The specific mechanism of action, active peptide ingredient, and targeted disease indications for PT105R are not fully disclosed in public sources, but the context and developer's portfolio suggest potential metabolic or endocrine applications, possibly related to synthetic peptides used in diabetes or metabolic disease[3][5][7][9].